

Referenzen Gynäkologenratgeber 01/2023

1. Bundesärztekammer. Richtlinie zur Herstellung und Anwendung von hämatopoetischen Stammzellzubereitungen. *Deutsches Ärzteblatt*. 2014.
2. Wang Y, Zhao S. Placental Blood Circulation. <https://www.ncbi.nlm.nih.gov/books/NBK53254/>. Updated January 1, 2010. Accessed April 30, 2019.
3. Christou I, Mallis P, Michalopoulos E, et al. Evaluation of Peripheral Blood and Cord Blood Platelet Lysates in Isolation and Expansion of Multipotent Mesenchymal Stromal Cells. *Bioengineering (Basel)*. 2018;5(1). doi:10.3390/bioengineering5010019.
4. Bundesamt für Justiz. Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz - AMG) § 13 Herstellungserlaubnis. https://www.gesetze-im-internet.de/amg_1976/__13.html. Updated July 22, 2019. Accessed July 22, 2019.
5. Bundesamt für Justiz. Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz - AMG) § 21 Zulassungspflicht. https://www.gesetze-im-internet.de/amg_1976/__21.html. Updated July 22, 2019. Accessed July 22, 2019.
6. Bundesamt für Justiz. Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz - AMG) § 21a Genehmigung von Gewebezubereitungen. https://www.gesetze-im-internet.de/amg_1976/__21a.html. Updated July 22, 2019. Accessed July 22, 2019.
7. Bundesamt für Justiz. Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz - AMG) § 22 Zulassungsunterlagen. https://www.gesetze-im-internet.de/amg_1976/__22.html. Updated July 22, 2019. Accessed July 22, 2019.
8. Bundesamt für Justiz. Verordnung über die Anwendung der Guten Herstellungspraxis bei der Herstellung von Arzneimitteln und Wirkstoffen und über die Anwendung der Guten fachlichen Praxis bei der Herstellung von Produkten menschlicher Herkunft (Arzneimittel- und Wirkstoffherstellungsverordnung - AMWHV) § 4 Personal. https://www.gesetze-im-internet.de/amwhv/__4.html. Updated July 22, 2019. Accessed July 22, 2019.
9. Galieva LR, Mukhamedshina YO, Arkhipova SS, Rizvanov AA. Human Umbilical Cord Blood Cell Transplantation in Neuroregenerative Strategies. *Front Pharmacol*. 2017;8:628. doi:10.3389/fphar.2017.00628.
10. Sieburg HB, Cattarossi G, Muller-Sieburg CE. Lifespan differences in hematopoietic stem cells are due to imperfect repair and unstable mean-reversion. *PLoS Comput Biol*. 2013;9(4):e1003006. doi:10.1371/journal.pcbi.1003006.
11. Pillay J, den Braber I, Vrisekoop N, et al. In vivo labeling with $^2\text{H}_2\text{O}$ reveals a human neutrophil lifespan of 5.4 days. *Blood*. 2010;116(4):625-627. doi:10.1182/blood-2010-01-259028.
12. Park YM, Bochner BS. Eosinophil survival and apoptosis in health and disease. *Allergy Asthma Immunol Res*. 2010;2(2):87-101. doi:10.4168/aair.2010.2.2.87.
13. Siracusa MC, Comeau MR, Artis D. New insights into basophil biology: initiators, regulators, and effectors of type 2 inflammation. *Ann N Y Acad Sci*. 2011;1217:166-177. doi:10.1111/j.1749-6632.2010.05918.x.
14. Patel AA, Zhang Y, Fullerton JN, et al. The fate and lifespan of human monocyte subsets in steady state and systemic inflammation. *J Exp Med*. 2017;214(7):1913-1923. doi:10.1084/jem.20170355.
15. Kaestner L, Bogdanova A. Regulation of red cell life-span, erythropoiesis, senescence, and clearance. *Front Physiol*. 2014;5:269. doi:10.3389/fphys.2014.00269.
16. Franco RS. Measurement of red cell lifespan and aging. *Transfus Med Hemother*. 2012;39(5):302-307. doi:10.1159/000342232.

17. Seifert M, Küppers R. Human memory B cells. *Leukemia*. 2016;30(12):2283-2292. doi:10.1038/leu.2016.226.
18. Broxmeyer HE. *StemBook: Cord blood hematopoietic stem cell transplantation**. Cambridge (MA); 2008. <https://www.ncbi.nlm.nih.gov/books/NBK44751/>. Accessed April 29, 2019.
19. Jin HJ, Bae YK, Kim M, et al. Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. *Int J Mol Sci*. 2013;14(9):17986-18001. doi:10.3390/ijms140917986.
20. Davies JE, Walker JT, Keating A. Concise Review: Wharton's Jelly: The Rich, but Enigmatic, Source of Mesenchymal Stromal Cells. *Stem Cells Transl Med*. 2017;6(7):1620-1630. doi:10.1002/sctm.16-0492.
21. Marino L, Castaldi MA, Rosamilio R, et al. Mesenchymal Stem Cells from the Wharton's Jelly of the Human Umbilical Cord: Biological Properties and Therapeutic Potential. *Int J Stem Cells*. 2019. doi:10.15283/ijsc18034.
22. Dalous J, Larghero J, Baud O. Transplantation of umbilical cord-derived mesenchymal stem cells as a novel strategy to protect the central nervous system: technical aspects, preclinical studies, and clinical perspectives. *Pediatr Res*. 2012;71(4 Pt 2):482-490. doi:10.1038/pr.2011.67.
23. Willing AE, Eve DJ, Sanberg PR. Umbilical cord blood transfusions for prevention of progressive brain injury and induction of neural recovery: an immunological perspective. *Regen Med*. 2007;2(4):457-464. doi:10.2217/17460751.2.4.457.
24. Balassa K, Rocha V. Anticancer cellular immunotherapies derived from umbilical cord blood. *Expert Opin Biol Ther*. 2018;18(2):121-134. doi:10.1080/14712598.2018.1402002.
25. Bönig H, Heiden M, Schüttrumpf J, Müller MM, Seifried E. Potenzial hämatopoetischer Stammzellen als Ausgangsmaterial für Arzneimittel für neuartige Therapien. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 2011;54(7):791-796. doi:10.1007/s00103-011-1305-2.
26. Mayani H, Wagner JE, Broxmeyer HE. Cord blood research, banking, and transplantation: achievements, challenges, and perspectives. *Bone Marrow Transplant*. 2019. doi:10.1038/s41409-019-0546-9.
27. Gluckman Eliane, Broxmeyer Hal E., Auerbach Arleen D., et al. Hematopoietic Reconstitution in a Patient with Fanconi's Anemia by Means of Umbilical-Cord Blood from an HLA-Identical Sibling // Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. *N Engl J Med*. 1989;321(17):1174-1178. doi:10.1056/NEJM198910263211707.
28. Dessels C, Alessandrini M, Pepper MS. Factors Influencing the Umbilical Cord Blood Stem Cell Industry: An Evolving Treatment Landscape. *Stem Cells Transl Med*. 2018;7(9):643-650. doi:10.1002/sctm.17-0244.
29. ClinicalTrials.gov. NCT03913312: Multicenter, One-arm, Phase II Clinical Study of Decitabine Combined With Unrelated Cord Blood Transplantation for the Treatment of Acute Myeloid Leukemia (AML) in the Elderly. <https://clinicaltrials.gov/ct2/show/NCT03913312>. Accessed August 16, 2022.
30. ClinicalTrials.gov. NCT03441958: A Phase I-II Open-label Study of Non-myeloablative-allogeneic Transplant of ECT-001 (UM171/ Fed-batch Culture System) Expanded Cord Blood in Patients With High-risk Multiple Myeloma. <https://clinicaltrials.gov/ct2/show/NCT03441958>. Accessed August 16, 2022.
31. ClinicalTrials.gov. NCT01451502: Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units. <https://clinicaltrials.gov/ct2/show/NCT01451502>. Accessed August 16, 2022.

32. ClinicalTrials.gov. NCT01861093: A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients. <https://clinicaltrials.gov/ct2/show/NCT01861093>. Accessed August 16, 2022.
33. ClinicalTrials.gov. NCT02730299: A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord[®], Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies. [Already published]. <https://clinicaltrials.gov/ct2/show/NCT02730299>. Accessed 16.08.22.
34. ClinicalTrials.gov. NCT01962636: Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological Diseases. <https://clinicaltrials.gov/ct2/show/NCT01962636>. Accessed August 16, 2022.
35. ClinicalTrials.gov. NCT03096782: Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma. <https://clinicaltrials.gov/ct2/show/NCT03096782>. Accessed August 16, 2022.
36. ClinicalTrials.gov. NCT00547196: Study of Four Different Chemotherapy Regimens With or Without Total-Body Irradiation Followed by Umbilical Cord Blood Transplant in Treating Patients With Relapsed or Refractory Hematologic Cancer. <https://clinicaltrials.gov/ct2/show/NCT00547196?recrs=abdf&cond=leukemia%2C+lymphoma&intr=umbilical+cord+blood&draw=2&rank=6>. Accessed August 16, 2022.
37. ClinicalTrials.gov. NCT00719888: Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease. <https://clinicaltrials.gov/ct2/show/NCT00719888?recrs=abdf&cond=leukemia%2C+lymphoma&intr=umbilical+cord+blood&draw=2&rank=10>. Accessed August 16, 2022.
38. ClinicalTrials.gov. NCT04083170: Cord Blood Transplant With OTS for the Treatment of HIV Positive Hematologic Cancers. <https://clinicaltrials.gov/ct2/show/NCT04083170>. Accessed August 16, 2022.
39. ClinicalTrials.gov. NCT02727803: Personalized NK Cell Therapy in Cord Blood Transplantation. <https://clinicaltrials.gov/ct2/show/NCT02727803>. Accessed August 16, 2022.
40. ClinicalTrials.gov. NCT02280525: Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma. <https://clinicaltrials.gov/ct2/show/NCT02280525>. Accessed August 16, 2022.
41. ClinicalTrials.gov. NCT03056339: Dose Escalation Study Phase I/II of Umbilical Cord Blood-Derived CAR-Engineered NK Cells in Conjunction With Lymphodepleting Chemotherapy in Patients With Relapsed/Refractory B-Lymphoid Malignancies. <https://clinicaltrials.gov/ct2/show/NCT03056339?term=%22cord+blood%22%2C+CAR%2C+NK&rank=1>. Accessed August 16, 2022.
42. ClinicalTrials.gov. NCT03420963: Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults. <https://clinicaltrials.gov/ct2/show/NCT03420963>. Accessed August 16, 2022.
43. ClinicalTrials.gov. NCT04796675: Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies. <https://clinicaltrials.gov/ct2/show/NCT04796675?recrs=abdf&cond=leukemia%2C+lymphoma&intr=umbilical+cord+blood&draw=3&rank=7>. Accessed August 16, 2022.
44. ClinicalTrials.gov. NCT05092451: Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignancies.

- <https://clinicaltrials.gov/ct2/show/NCT05092451?recrs=abdf&cond=leukemia%2C+lymphoma&intr=umbilical+cord+blood&draw=3&rank=11>. Accessed August 16, 2022.
45. ClinicalTrials.gov. NCT02551003: A Multi-Centre Safety and Efficacy Study of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonates Encephalopathy in China. <https://clinicaltrials.gov/ct2/show/NCT02551003>. Accessed August 16, 2022.
 46. ClinicalTrials.gov. NCT02881970: Neonatal Hypoxic Ischemic Encephalopathy : Safety and Feasibility Study of a Curative Treatment With Autologous Cord Blood Stem Cells (NEOSTEM). <https://clinicaltrials.gov/ct2/show/NCT02881970>. Accessed August 16, 2022.
 47. ClinicalTrials.gov. NCT02433509: Phase I Clinical Safety Study About Human Umbilical Cord Blood Monocyte in the Acute Ischemic Stroke. <https://clinicaltrials.gov/ct2/show/NCT02433509>. Accessed August 16, 2022.
 48. ClinicalTrials.gov. NCT04243408: Treatment of Children With Cerebral Palsy With Autologous Umbilical Cord Blood, a Pilot Study. <https://clinicaltrials.gov/ct2/show/NCT04243408?recrs=abdf&cond=cerebral+palsy&intr=cord+blood&draw=2&rank=1>. Accessed August 16, 2022.
 49. ClinicalTrials.gov. NCT04013646: Combination Therapy of Umbilical Cord Blood and Erythropoietin for Stroke Patients. <https://clinicaltrials.gov/ct2/show/NCT04013646?recrs=abdf&cond=stroke&intr=cord+blood&draw=2&rank=3>. Accessed August 16, 2022.
 50. ClinicalTrials.gov. NCT03779711: Phase IIb Study of Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Stage II Surgical Repair of Right Ventricular Dependent Variants of Hypoplastic Left Heart Syndrome (AutoCell-S2). <https://clinicaltrials.gov/ct2/show/NCT03779711>. Accessed June 21, 2019.
 51. ClinicalTrials.gov. NCT03558269: Pilot Study to Assess the Efficacy of Autologous Umbilical Cord Blood Treatment of Brain and Heart Injury in Neonates With Congenital Heart Defect. <https://clinicaltrials.gov/ct2/show/NCT03558269>. Accessed August 17, 2022.
 52. ClinicalTrials.gov. NCT04907526: Intramyocardial Injection of Autologous UCB-MNC During Fontan Surgery for SRV Dependent CHD. <https://clinicaltrials.gov/ct2/show/NCT04907526?recrs=abdf&cond=heart&intr=cord+blood&draw=2&rank=3>. Accessed August 17, 2022.
 53. ClinicalTrials.gov. NCT01632475: Long Term Follow-Up Study of the Safety and Exploratory Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia. <https://clinicaltrials.gov/ct2/show/NCT01632475>. Accessed August 17, 2022.
 54. ClinicalTrials.gov. NCT03378063: Stem Cells for Bronchopulmonary Dysplasia: a Cohort Study. <https://clinicaltrials.gov/ct2/show/NCT03378063?term=NOT+peripheral&recrs=abdf&intr=%22cord+blood%22&draw=2&rank=124>. Accessed August 17, 2022.
 55. ClinicalTrials.gov. NCT05071638: Effect of Autologous Cord Blood Mononuclear Cells for Treatment of Bronchopulmonary Dysplasia in Extremely Preterm Neonates. <https://clinicaltrials.gov/ct2/show/NCT05071638?recrs=abdf&cond=lung&intr=cord+blood&draw=2&rank=2>. Accessed August 17, 2022.
 56. ClinicalTrials.gov. NCT04440670: Effect of Autologous Cord Blood Mononuclear Cells for Prevention of Bronchopulmonary Dysplasia in Extremely Preterm Neonates. <https://clinicaltrials.gov/ct2/show/NCT04440670?recrs=abdf&cond=lung&intr=cord+blood&draw=2&rank=3>. Accessed August 17, 2022.
 57. ClinicalTrials.gov. NCT04003857: Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial.

- <https://clinicaltrials.gov/ct2/show/NCT04003857?recrs=abdf&cond=lung&intr=cord+blood&draw=2&rank=8>. Accessed August 17, 2022.
58. ClinicalTrials.gov. NCT03835312: Sequential Transplantation of Umbilical Cord Blood Stem Cells and Islet Cells in Children and Adolescents With Monogenic Immunodeficiency Type 1 Diabetes Mellitus. <https://clinicaltrials.gov/ct2/show/NCT03835312>. Accessed August 17, 2022.
 59. ClinicalTrials.gov. NCT03773328: A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS). <https://clinicaltrials.gov/ct2/show/NCT03773328?recrs=abdf&cond=autoimmune&intr=cord+blood&draw=2&rank=6>. Accessed August 17, 2022.
 60. ClinicalTrials.gov. NCT04943289: Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis (DUOC for MS). <https://clinicaltrials.gov/ct2/show/NCT04943289?recrs=abdf&cond=autoimmune&intr=cord+blood&draw=2&rank=5>. Accessed August 17, 2022.
 61. ClinicalTrials.gov. NCT04882683: Clinical Study of Cord Blood Mononuclear Cells on Treatment of Hormone-resistant or Hormone-dependent Ulcerative Colitis. <https://clinicaltrials.gov/ct2/show/NCT04882683?recrs=abdf&cond=ulcer&intr=cord+blood&draw=2&rank=3>. Accessed August 17, 2022.
 62. ClinicalTrials.gov. NCT02254863: Augmentation of Umbilical Cord Blood Transplantation for Inherited Metabolic Diseases With Intrathecal Administration of Human Umbilical Cord Blood-Derived Oligodendrocyte-Like Cells. <https://clinicaltrials.gov/ct2/show/NCT02254863>. Accessed July 21, 2021.
 63. ClinicalTrials.gov. NCT03016806: Umbilical Cord Blood Transplantation From Unrelated Donors. <https://clinicaltrials.gov/ct2/show/NCT03016806>. Accessed August 17, 2022.
 64. ClinicalTrials.gov. NCT01962415: Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT (HSCT+RIC). <https://clinicaltrials.gov/ct2/show/NCT01962415?recrs=abdf&cond=Metabolic+Disease&intr=cord+blood&draw=2&rank=7>. Accessed August 17, 2022.
 65. Hansen M, Zatula N, Riammer S, Lehmann M. Safe enzymatic isolation and expansion of mesenchymal stromal cells from cryopreserved umbilical cord tissue. *JCB*. 2019;4(1-2):51-56. doi:10.3233/JCB-180011.
 66. Beeravolu N, McKee C, Alamri A, et al. Isolation and Characterization of Mesenchymal Stromal Cells from Human Umbilical Cord and Fetal Placenta. *J Vis Exp*. 2017;(122). doi:10.3791/55224.
 67. Arutyunyan I, Elchaninov A, Makarov A, Fatkhudinov T. Umbilical Cord as Prospective Source for Mesenchymal Stem Cell-Based Therapy. *Stem Cells Int*. 2016;2016:6901286. doi:10.1155/2016/6901286.
 68. Park YB, Ha CW, Kim JA, et al. Single-stage cell-based cartilage repair in a rabbit model: cell tracking and in vivo chondrogenesis of human umbilical cord blood-derived mesenchymal stem cells and hyaluronic acid hydrogel composite. *Osteoarthr Cartil*. 2017;25(4):570-580. doi:10.1016/j.joca.2016.10.012.
 69. Kargozar S, Mozafari M, Hashemian SJ, et al. Osteogenic potential of stem cells-seeded bioactive nanocomposite scaffolds: A comparative study between human mesenchymal stem cells derived from bone, umbilical cord Wharton's jelly, and adipose tissue. *J Biomed Mater Res Part B Appl Biomater*. 2018;106(1):61-72. doi:10.1002/jbm.b.33814.
 70. Yang C, Wang G, Ma F, et al. Repeated injections of human umbilical cord blood-derived mesenchymal stem cells significantly promotes functional recovery in rabbits with spinal cord

injury of two noncontinuous segments. *Stem Cell Res Ther.* 2018;9(1):136. doi:10.1186/s13287-018-0879-0.

71. Ertl J, Pichlsberger M, Tuca A-C, et al. Comparative study of regenerative effects of mesenchymal stem cells derived from placental amnion, chorion and umbilical cord on dermal wounds. *Placenta.* 2018;65:37-46. doi:10.1016/j.placenta.2018.04.004.
72. Moroncini G, Paolini C, Orlando F, et al. Mesenchymal stromal cells from human umbilical cord prevent the development of lung fibrosis in immunocompetent mice. *PLoS ONE.* 2018;13(6):e0196048. doi:10.1371/journal.pone.0196048.
73. ClinicalTrials.gov. NCT05054803: Cell Therapy for Chronic Traumatic Cervical Incomplete Spinal Cord Injury. <https://clinicaltrials.gov/ct2/show/NCT05054803?term=spinal+cord&recrs=abdf&intr=UC-MS&draw=2&rank=1>. Accessed August 17, 2022.
74. ClinicalTrials.gov. NCT04414592: Human Umbilical Cord Mesenchymal Stem Cells For the Treatment of Lumbar Disc Degeneration Disease. <https://clinicaltrials.gov/ct2/show/NCT04414592?term=spinal+cord&recrs=abdf&intr=UC-MS&draw=2&rank=3>. Accessed August 17, 2020.
75. ClinicalTrials.gov. NCT04314687: Allogeneic Umbilical Cord Mesenchymal Stem Cells and Conditioned Medium for Cerebral Palsy in Children. <https://clinicaltrials.gov/ct2/show/NCT04314687>. Accessed August 17, 2022.
76. ClinicalTrials.gov. NCT04873752: A Study to Investigate the Safety and Efficacy of UC-MSCs in Pediatric Patients With Cerebral Palsy. <https://clinicaltrials.gov/ct2/show/NCT04873752?recrs=abdf&cond=cerebral+palsy&intr=UC-MS&draw=2&rank=1>. Updated February 14, 2022.000Z. Accessed August 17, 2022.
77. ClinicalTrials.gov. NCT05490173: The Pilot Experimental Study of the Neuroprotective Effects of Exosomes in Extremely Low Birth Weight Infants. <https://clinicaltrials.gov/ct2/show/NCT05490173?term=cerebral+palsy&recrs=abdf&intr=UC-MS&draw=2&rank=3>. Accessed August 17, 2022.
78. ClinicalTrials.gov. NCT03383081: A Clinical Research on the Safety/Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-OA) Therapy for Patients With Osteoarthritis. <https://clinicaltrials.gov/ct2/show/NCT03383081>. Accessed August 17, 2022.
79. ClinicalTrials.gov. NCT05160831: Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Knee Osteoarthritis. <https://clinicaltrials.gov/ct2/show/NCT05160831?term=Osteoarthritis&recrs=abdf&intr=UC-MS&draw=2&rank=1>. Accessed August 17, 2022.
80. ClinicalTrials.gov. NCT02805855: Autologous Culture Expanded Mesenchymal Stromal Cells for Knee Osteoarthritis. <https://clinicaltrials.gov/ct2/show/NCT02805855?recrs=abdf&cond=Osteo+Arthritis&intr=UC-MS&draw=2&rank=2>. Accessed August 19, 2022.
81. ClinicalTrials.gov. NCT05016011: Efficacy of Allogeneic UCMSCs for Treating Large Defects Knee Injury. <https://clinicaltrials.gov/ct2/show/NCT05016011?recrs=abdf&cond=Osteo+Arthritis&intr=UC-MS&draw=2&rank=4>. Accessed August 19, 2022.
82. ClinicalTrials.gov. NCT04314661: Comparative Effectiveness of Arthroscopy and Non-Arthroscopy Using Mesenchymal Stem Cell Therapy (MSCs) and Conditioned Medium for Osteoarthritis (OA). <https://clinicaltrials.gov/ct2/show/NCT04314661?recrs=abdf&cond=Osteo+Arthritis&intr=UC-MS+NOT+adipose&draw=2&rank=4>. Accessed August 19, 2022.

83. ClinicalTrials.gov. NCT04011059: Randomized Study as Proof of Concept of Coronary Revascularization Surgery With Injection of Wharton's Jelly-derived Mesenchymal Cells and Placement of an Epicardial Extracellular Matrix Patch Seeded With WJ-MSCs in Patients With Ischemic Cardiomyopathy. <https://clinicaltrials.gov/ct2/show/NCT04011059>. Accessed August 19, 2022.
84. ClinicalTrials.gov. NCT04992832: Multi-intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Heart Failure With Reduced Ejection Fraction (PRIME-HFrEF Study) (PRIME-HFrEF). <https://clinicaltrials.gov/ct2/show/NCT04992832?recrs=abdf&cond=heart&intr=UC-MS&draw=2&rank=1>. Accessed August 19, 2022.
85. ClinicalTrials.gov. NCT04939077: Treatment of Heart Failure Using Human Umbilical Cord Mesenchymal Stem Cells(hUC-MSC). <https://clinicaltrials.gov/ct2/show/NCT04939077?recrs=abdf&cond=heart&intr=UC-MS&draw=2&rank=2>. Accessed August 19, 2022.
86. ClinicalTrials.gov. NCT05043610: MSCs for Prevention of MI-induced HF (PREVENT-TAHA). <https://clinicaltrials.gov/ct2/show/NCT05043610?recrs=abdf&cond=heart&intr=UC-MS&draw=2&rank=5>. Accessed August 19, 2022.
87. ClinicalTrials.gov. NCT03902067: UC-MSC Transplantation for Left Ventricular Dysfunction After AMI. <https://clinicaltrials.gov/ct2/show/NCT03902067?recrs=abdf&cond=heart&intr=UC-MS&draw=2&rank=1>. Updated February 14, 2022.000Z. Accessed February 14, 2022.725Z.
88. ClinicalTrials.gov. NCT03562065: Treatment of Refractory Systemic Lupus Erythematosus by Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord (MSC-SLE). <https://clinicaltrials.gov/ct2/show/NCT03562065>. Accessed August 19, 2022.
89. ClinicalTrials.gov. NCT04971980: Safety and Efficacy Study of Human Umbilical Cord-Derived Mesenchymal Stem Cells(BC-U001) for Rheumatoid Arthritis. <https://www.clinicaltrials.gov/ct2/show/NCT04971980?recrs=abdf&cond=autoimmune&intr=UC-MS&draw=2&rank=1>. Accessed August 19, 2022.
90. ClinicalTrials.gov. NCT03828344: Safety and Tolerability of a Single Intravenous Infusion of BX-U001 in Refractory Rheumatoid Arthritis. <https://www.clinicaltrials.gov/ct2/show/NCT03828344?recrs=abdf&cond=autoimmune&intr=UC-MS&draw=2&rank=2>. Accessed August 19, 2022.
91. ClinicalTrials.gov. NCT05061030: Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents. <https://www.clinicaltrials.gov/ct2/show/NCT05061030?recrs=abdf&cond=autoimmune&intr=UC-MS&draw=2&rank=3>. Accessed August 19, 2022.
92. ClinicalTrials.gov. NCT05286255: Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias. <https://clinicaltrials.gov/ct2/show/NCT05286255?recrs=abdf&cond=COVID-19&intr=UC-MS&draw=2&rank=2>. Accessed August 23, 2022.
93. ClinicalTrials.gov. NCT04345601: Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease). <https://clinicaltrials.gov/ct2/show/NCT04345601?recrs=abdf&cond=COVID-19&intr=UC-MS&draw=2&rank=5>. Accessed August 23, 2022.
94. ClinicalTrials.gov. NCT04452097: Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS. <https://clinicaltrials.gov/ct2/show/NCT04452097?recrs=abdf&cond=COVID-19&intr=UC-MS&draw=2&rank=9>. Accessed August 23, 2022.
95. ClinicalTrials.gov. NCT04896853: Treatment of Respiratory Complications Associated With COVID-19 Infection Using ProTrans®.

<https://clinicaltrials.gov/ct2/show/NCT04896853?recrs=abdf&cond=COVID-19&intr=UC-MS&draw=2&rank=11>. Accessed August 23, 2022.

96. ClinicalTrials.gov. NCT05433298: Mesenchymal Stromal Cells for the Treatment of Patients With COVID-19. <https://clinicaltrials.gov/ct2/show/NCT05433298?recrs=abdf&cond=COVID-19&intr=UC-MS&draw=2&rank=12>. Accessed August 23, 2022.